Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2001
05/22/2001US6235285 An isolated polypeptide comprising a heterologous amino acid sequence fused to specific polynucleotide sequence
05/22/2001US6235281 Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
05/22/2001US6235279 Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins
05/22/2001US6235263 Carboxy-terminal BRCA1 interacting protein
05/22/2001CA1341235C Modular assembly of antibody genes, antibodies prepared thereby and use
05/21/2001WO2001036465A2 Human zven proteins
05/21/2001CA2392128A1 Human zven proteins
05/17/2001WO2001035102A2 Diagnosis and treatment of malignant neoplasms
05/17/2001WO2001034843A1 Lentiviral vector transduction of hematopoietic stem cells
05/17/2001WO2001034828A1 Process for producing tripeptides
05/17/2001WO2001034827A1 Antisense modulation of rank expression
05/17/2001WO2001034804A1 Human membrane proteins and polynucleotides encoding the same
05/17/2001WO2001034802A2 Compositions and methods for the therapy and diagnosis of prostate cancer
05/17/2001WO2001034801A2 Recombinant gelatin in vaccines
05/17/2001WO2001034800A1 19 human secreted proteins
05/17/2001WO2001034799A1 6 human secreted proteins
05/17/2001WO2001034798A1 Cloning and characterization of viral iap associated factor (viaf) in several organisms
05/17/2001WO2001034796A1 Chordin-like homologs
05/17/2001WO2001034794A1 Casb7434, an antigen over-expressed in colon cancer
05/17/2001WO2001034793A1 Method of effecting dna splicing
05/17/2001WO2001034792A2 Compositions and methods for the diminution or elimination of various cancers
05/17/2001WO2001034785A1 Novel metalloprotease having aggrecanase activity
05/17/2001WO2001034781A2 Lytic enzymes useful for treating fungal infections
05/17/2001WO2001034779A2 Human proteins with homology to carboxypeptidases and polynucleotides encoding the same
05/17/2001WO2001034774A2 Method for protection of mammalian cells by means of over-expressed g-2/m cell cycle coupler
05/17/2001WO2001034769A2 24 human secreted proteins
05/17/2001WO2001034768A2 15 human secreted proteins
05/17/2001WO2001034767A2 22 human secreted proteins
05/17/2001WO2001034654A1 Hedgehog fusion proteins and uses
05/17/2001WO2001034648A1 Reduced side-effect hemoglobin compositions
05/17/2001WO2001034646A2 Recombinant gelatins
05/17/2001WO2001034645A2 Mutated il-13 molecules and their uses
05/17/2001WO2001034644A1 15 human secreted proteins
05/17/2001WO2001034643A1 24 human secreted proteins
05/17/2001WO2001034641A2 Antimicrobial activity of the first cationic cluster of human lactoferrin
05/17/2001WO2001034640A2 Peptide (virip) which inhibits a circulating virus in humans and the use thereof
05/17/2001WO2001034638A1 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
05/17/2001WO2001034637A1 Novel physiologically active peptides and process for producing the same
05/17/2001WO2001034636A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
05/17/2001WO2001034633A2 Methods for treatment of human huntington's disease and methods of screening for active agents
05/17/2001WO2001034631A2 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
05/17/2001WO2001034630A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
05/17/2001WO2001034629A1 21 human secreted proteins
05/17/2001WO2001034628A1 35 human secreted proteins
05/17/2001WO2001034627A1 28 human secreted proteins
05/17/2001WO2001034626A1 28 human secreted proteins
05/17/2001WO2001034625A1 Isolation and characterization of human nf-e4
05/17/2001WO2001034623A1 29 human secreted proteins
05/17/2001WO2001034621A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies
05/17/2001WO2001034594A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
05/17/2001WO2001034593A1 Compound with growth hormone releasing properties
05/17/2001WO2001034574A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
05/17/2001WO2001034549A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
05/17/2001WO2001034225A2 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
05/17/2001WO2001034208A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
05/17/2001WO2001034206A2 Nucleic acid-containing complex
05/17/2001WO2001034205A2 Use of lytic toxins and toxin conjugates
05/17/2001WO2001034188A1 Malaria vaccine
05/17/2001WO2001034183A2 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
05/17/2001WO2001034182A2 Composition for treating respiratory tract infections containing menthol, eucalyptol and an alpha-amylase
05/17/2001WO2001034181A2 Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene
05/17/2001WO2001034180A2 Interferon gamma for the treatment of asthma
05/17/2001WO2001034179A1 Method of inducing angiogenesis
05/17/2001WO2001034178A2 Methods and compositions for treatment of traumatic brain injury
05/17/2001WO2001034177A2 Method of treating a viral infection using antagonists of macrophage colony stimulating factor
05/17/2001WO2001034176A1 A method and composition for treating prostate cancer
05/17/2001WO2001034175A2 Methods of treating inflammatory bowel disease using cholera toxin b subunit
05/17/2001WO2001034174A2 Methods for administration of therapeutic agents on an antiangiogenic schedule
05/17/2001WO2001034173A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
05/17/2001WO2001034171A2 Peptides for treatment of erectile dysfunction
05/17/2001WO2001034166A1 Transplant/implant device and method for its production
05/17/2001WO2001034165A1 Therapeutic compositions and methods of use thereof
05/17/2001WO2001034157A1 Protease inhibitors
05/17/2001WO2001034138A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
05/17/2001WO2001034115A2 Method for encapsulating proteins or peptides in liposomes, liposomes produced using said method, and their use
05/17/2001WO2001034095A2 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t
05/17/2001WO2001034088A2 Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders
05/17/2001WO2001033977A1 Product and method for control of obesity
05/17/2001WO2001033965A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
05/17/2001WO2001033964A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
05/17/2001WO2001028353A8 Protein hydrolysates produced with the use of marine proteases
05/17/2001WO2001026646A8 NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF
05/17/2001WO2001018043A3 Neurogenic compositions and methods
05/17/2001WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
05/17/2001WO2001011013A3 The interaction of smad6 with hox proteins and uses thereof
05/17/2001WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
05/17/2001WO2001007602A3 Oligonucleotides for inhibiting the expression of human eg5
05/17/2001WO2001007471A9 Cell cycle and proliferation proteins
05/17/2001WO2001005810A3 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6?
05/17/2001WO2001005427B1 Psca: prostate stem cell antigen and uses thereof
05/17/2001WO2001004157A3 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS
05/17/2001WO2001000662A3 The use of human fgh-8 polypeptides as neurotrophic agents
05/17/2001WO2000078796A3 Labeled neurotensin derivatives with improved resistance to enzymatic degradation
05/17/2001WO2000077166A3 Gene expression modulated in gastrointestinal inflammation
05/17/2001WO2000066622A9 T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
05/17/2001WO2000062742A3 Methods for regulating the condition of mammalian keratinous tissue
05/17/2001WO2000049038A9 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof
05/17/2001WO2000041484A3 Novel use of phospholipids of vegetable and animal origin in nutritional therapy
05/17/2001WO2000040613A9 Insulin-like growth factor (igf) i mutant variants
05/17/2001WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto